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ABSTRACT 
Vascular calcification (VC) is a complication of chronic kidney disease which predicts 
morbidity and mortality. Uremic serum promotes VC, but the mechanism involved is 
unknown. A role for 1,25(OH)2D3 on VC has been proposed, but the mechanism is 
unclear because both, low and high levels have been shown to increase it. In this paper 
we investigate the role of 1,25(OH)2D3 produced in vascular smooth muscle cells 
(VSMCs) on VC.  Rats with subtotal nephrectomy and kidney recipient patients 
showed increased arterial expression of 1α-hydroxylase in vivo. VSMCs exposed in 
vitro to serum obtained from uremic rats also showed increased 1α-hydroxylase 
expression. Those increases were parallel to an increase in VC. After 6 days with high 
phosphate media, VSMCs overexpressing 1α-hydroxylase show significantly higher 
calcium content and RUNX2 expression than control cells. 1α-hydroxylase null mice 
(KO) with subtotal nephrectomy and treated with calcitriol (400 ng/kg) for two weeks 
showed significantly lower levels of vascular calcium content, alizarin red staining and 
RUNX2 expression than wild type (WT) littermates. Serum calcium, phosphorus, 
BUN, PTH and 1,25(OH)2D3  levels were similar in both calcitriol-treated groups. In 
vitro, WT VSMCs treated with uremic serum also showed a significant increase in 1α-
hydroxylase expression and higher calcification that was not observed in KO cells. We 
conclude that local activation of 1α-hydroxylase in the artery mediates VC observed in 
uremia. 
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INTRODUCTION 
Cardiovascular mortality is the leading cause of death in chronic kidney disease (CKD) 
patients. These patients develop extensive vascular calcification, a condition which has 
been linked to higher cardiovascular morbidity and mortality.(1,2) Vascular calcification 
(VC) increases vascular stiffness and reduces vascular compliance, which in turn 
increase systolic blood pressure, pulse pressure, and pulse wave velocity. All of these 
complications can lead to hypertension, heart failure, altered coronary perfusion and left 
ventricular hypertrophy.(3) In the past, vascular calcification was regarded as a passive 
process in which increased calcium and phosphate levels over its solubility threshold 
would induce calcium mineral deposition in soft tissues. However, recent data 
demonstrate that VC is a regulated process similar to bone formation where calcification 
inducers and inhibitors have an active role.(4) On the one hand, an increase of inducers 
of VC such as RANKL,(5) RUNX2,(6) osteonectin,(7) osteocalcin(8) or BMP2 promote the 
osteoblastic phenotype of VSMC.(9) These osteoblastic markers are found to be elevated 
in the vasculature of both uremic rats and CKD patients.(10) On the other hand a 
decrease of inhibitors of vascular calcification, such as MGP, osteopontin, fetuin(11) and 
osteoprotegerin, is also found in CKD(12) and could also play a role in the increased 
vascular calcification levels observed in uremia. 
Treatments with 1,25(OH)2D3 or other VDR agonists are used in CKD patients in order 
to reduce secondary hyperparathyroidism and prevent excessive bone resorption. Both 
low and high 1,25(OH)2D3 levels have been proven to enhance VC.(13) An excess of 
1,25(OH)2D3 is arteriotoxic and induces vascular calcifications in humans and 
experimental animals,(14,15) while vitamin D deficiency reduces the levels of 
calcification inhibitors and increases the inflammatory response, contributing to 
increased VC.(13,16) Consequently, tight regulation of active vitamin D levels is 
important in maintaining a healthy vessel wall. Vitamin D3 is either consumed in the 
diet or produced by UVB photoconversion of 7-dehydrocholesterol in skin. Vitamin D3 
is first metabolized to 25 hydroxyvitaminD3 in the liver and subsequently to the active 
form 1,25(OH)2D3 by the enzyme 1α-hydroxylase (cyp27b1).(17) 1α-hydroxylase action 
is the limiting step in active vitamin D biosynthesis and its activity in the kidney is 
tightly regulated by 1,25(OH)2D3 by a negative feedback loop, and by other factors 
related to mineral metabolism such as PTH and FGF23. In addition to a regulation of its 
activation, the levels of 1,25(OH)2D3 are also affected by the rate of degradation. The 
metabolism is mediated by the enzyme 24-hydroxylase, which is responsible for the 
hydroxylation of 25(OH)D3 and 1,25(OH)2D3 to obtain 24,25(OH)2D3 and 
1,24,25(OH)2D3, respectively.(18) 1α-hydroxylase is mainly located in the kidney but it 
can be found in a wide number of extra-renal tissues where it is regulated independently 
from the renal enzyme.(19) Thus, the expression of 1α-hydroxylase has been detected in 
endothelial cells,(20) VSMC,(21,22) parathyroid gland,(23) cells from the colon mucosa,(24) 
macrophages(25) and in keratinocytes(26) raising numerous questions about the 
physiological role of local endogenous 1,25(OH)2D3 production. Thus, in the 
vasculature, Zehnder et al.(20) postulated that the synthesis of 1,25(OH)2D3 by 
endothelial cells has a paracrine/autocrine function and acts at a local level regulating 
leukocyte adhesion. Furthermore, its activity seems to be regulated in a different way 
than the renal isoform. For instance, production of active vitamin D is upregulated by 
proinflammatory cytokines in endothelial cells(20) or in trophoblasts.(27) In addition, 
some data point to a deregulation of extrarenal vitamin D metabolism in several 
conditions such as pancreatic disease,(28) human granuloma-forming disease,(29) 
cancer(30) or even uremia. Thus, in chronic renal failure, peripheral macrophages 
exhibited an enhanced 1α-hydroxylase activity and a decreased capacity to degrade 
1,25(OH)2D3.(31)  
The fact that VSMC express all the proteins involved in 1,25(OH)2D3 metabolism 
(VDR, 1-αhydroxylase and 24-hydroxylase) and the U-shaped relationship of active 
vitamin D levels and vascular calcification led us to analyze the role of locally activated 
vitamin D in vascular calcification. In the present work, we analyze the role of the local 
synthesis of calcitriol on uremia-induced vascular calcification. 
 
 
 
METHODS 
In Vivo Study 
All the animal studies performed followed the NIH Guide for the Care and Use of 
Laboratory Animals and were approved by the local Animal Ethics Committees in 
accordance with the guidelines of European Research Council for the care and use of 
laboratory animals. In all surgical procedures performed in animals, isoflurane was used 
as anesthetic and bruprenorphine was used as analgesic after the surgery. 
Studies involving human samples were performed in agreement with the Declaration of 
Helsinki and with local and national laws. The Human Ethics Committee of the 
Hospital Universitario Central de Asturias approved the study procedures, and all 
participants signed an informed consent before inclusion in the study, providing 
permission for their medical data to be anonymously used for research. 
Human epigastric artery samples 
Part of this study comprised 9 patients with chronic kidney disease who showed clinical 
calcification and 10 kidney donors with normal renal function non-smokers and free 
from diabetes and cardiovascular disease. Both arterial samples were obtained during 
the transplantation procedure (in the case of the CKD patients) or in the organ extraction 
process after signing informed consent. 
Model of CKD in Rats 
Sprague-Dawley rats (200-225g) underwent 5/6 nephrectomy as previously 
described.(32) Rats were anesthetized and right nephrectomy was performed. After 1 
week, animals were subjected to 2/3 nephrectomy of the left kidney by ligation of the 
renal parenchyma in both renal poles. Another group of sham-operated rats were used as 
control (n=8). At sacrifice, 8 weeks later, abdominal aortas were collected and 
processed to isolate RNA, protein and to determine calcium content. Serum from sham 
and 5/6 nephrectomy rats was collected and processed to be used in the in vitro 
experiments. 
 
Generation and Characterization of CYP27B1-/- Mice 
1α-hydroxylase KO mice (CYP27B1-/-) were provided by Dr. David Goltzman 
(Montreal, Canada) and were generated by ablation of exon 6 to exon 9.(33) These mice 
were bred to C57/BL6 wild type animals and the heterozygous offspring were crossed 
to produce CYP27B1-/- and CYP27B1 +/+ animals. CYP27B1-/- mice were fed a 
rescue diet; high Calcium diet (2% calcium, 1.25% phosphorus, 20% lactose and 2.2 
IU/g vitamin D3, Harlan Teklad, TD.96348) during growth and maintenance. Before 
starting the experimental process the diet was changed to a standard mouse chow (0.6% 
Ca 2+, 0.8% phosphorus, and 0.6 IU / g vitamin D3, Harlan Teklad) to avoid interference 
of the diet with the different treatments.  
Model of CKD in mice 
Subtotal nephrectomy (STN) was induced in 10-12-week-old mice after the two-step 
surgical procedure for 75% nephron reduction. Briefly, the parenchyma of the left 
kidney was reduced by 50%. The kidney was exposed, decapsulated and carefully 
cauterized, reducing the parenchyma of the upper and the lower pole. After 1-week of 
recovery period, right-sided total nephrectomy was performed. Treatments started one 
week after nephrectomy to facilitate the recovery after the operation. A group of sham-
operated mice was used as control in the present study (CYP27B1+/+, n=7, CYP27B1-
/-, n= 6). 
Subtotally nephrectomized CYP27B1+/+ and CYP27B1-/- were treated daily with 
calcitriol (400ng/kg) during 15 days (each group, n=8). At sacrifice, blood was collected 
and aortas were divided in two parts, one frozen in liquid nitrogen for calcium content 
determination and the other one fixed in formalin solution followed by processing and 
paraffin embedding. 
Serum biochemical analysis 
Blood was collected by cardiac puncture and centrifuged at 2500 rpm for 10 minutes at 
4ºC to obtain serum. 
Ca2+ and P were analyzed by a standard colorimetric analysis in the Biochemistry 
service of the Arnau de Vilanova Hospital (HUAV) in Lleida. BUN was determined by 
colorimetric assay, using the QuantiChrom Urea assay kit (DIUR-500). Immnunoassays 
were used to determine 1,25-DihydroxyvitaminD (1,25-dihydroxy VitaminD EIA, IDS), 
and also PTH (PTH mouse ELISA kit, Immunotopics). 
Quantitative analysis of aortic calcium 
Aortic tissue was desiccated for 20-24 hours at 60 °C, crushed to a powder with a pestle 
and mortar and decalcified with HCl (1N) at 4 °C, and then vortexed for 16 hours. After 
centrifugation, supernatant was collected and calcium content determined 
colorimetrically using the o-cresolphthalein complexone method, while protein content 
was determined by the Lowry method (Bio-Rad). Aortic calcium content was 
normalized by the protein amount in the sample and expressed as ng Ca/ mg of protein.  
Histology and immunohistochemistry 
Immunostaining for CYP27B1 (Cloud-Clone Corp, TX, USA) and RUNX2 (NBP1-
01004, Novus Biologicals) were carried out on 5-μm thick tissue sections of human 
epigastric arteries or mice aortas respectively. Tissue sections were deparaffinized 
through xylene and rehydrated through graded ethanol concentrations into distilled 
water, as previously described.(34) Shortly, antigen retrieval was done by boiling the 
slides in 10 mM citrate buffer (pH 6) for 10 minutes. Endogenous peroxidase quenching 
(30 minutes incubation in 0.66% (v/v) H2O2/PBS)) was followed by blocking of non-
specific binding with normal horse blocking serum (Vector Laboratories) for 30 min at 
RT. Anti-rabbit CYP27B1 (1/100) or RUNX2 antibody (1/50) were incubated overnight 
at 4ºC. After washing with PBS, slides were treated with corresponding biotinylated 
secondary antibody (30 minutes, RT), which was followed by the avidin-biotin-
peroxidase complex (30 minutes, RT) and 3, 3’-diaminobenzidine (DAB) as a 
chromogen (10 minutes, RT) (Vector Laboratories). Sections were counterstained with 
Mayer´s Hematoxylin to visualize the nuclei. Negative controls were performed by 
incubation with non-immune serum in place of a specific antibody, which resulted in a 
complete absence of staining. Stained tissue sections were examined using a Nikon 
Eclipse 80i microscope with a Nikon automatic camera system. Immunohistochemical 
results of CYP27B1 staining were evaluated following the uniform pre-established 
criteria. Staining intensity and % positive cells were graded semiquantitatively. 
Histological scores were obtained from each sample as follows: histoscore = 1 x (% 
light staining) + 2 x (% moderate staining) + 3 x (% strong staining), which ranged from 
0 (no immunoreaction) to 300 (maximum immunoreactivity). The reliability of such 
scores for interpretation of immunohistochemical staining of tissue sections has been 
shown previously.(35) 
For calcium staining in aortic sections, samples were deparaffinized, rehydrated and 
stained in 2% alizarin red solution (Sigma A3757) at pH between 4,1-4,3 for 5 minutes. 
After staining, samples were rehydrated with acetone, acetone-xylene (1:1), xylene and 
mounted in synthetic mounting medium (DPX). 
 In Vitro Study 
VSMC cultures from rat and mice (CYP27B1-/- and CYP27B1+/+) 
Primary rat and mose aortic VSMCs were obtained as previously described22 and 
maintained in DMEM (GIBCO) containing 10% FBS. Cells were plated (105 
cells/plate) in 100mm plates. When the cell confluence was about 80% VSMCs were 
shifted to treatment media, DMEM containing 15% serum from normal rats or 15% 
serum from 5/6 nephrectomized rats, 10 mmol/L sodium pyruvate, 10 mmol/L ß-
glycerophosphate (Sigma). Final concentration of calcium was adjusted to 4mM.  
VSMC between passage 2 and 8 were used in all the experiments. Every experiment 
was performed in triplicate, with three replicates per condition.  
Determination of VSMC calcification 
In all the calcification experiments, calcium levels were measured 6 days after the 
addition of the treatments (control serum and uremic serum). Cells were collected with 
PBS, centrifuged and the pellet was incubated with 50µl of HCL 0,6N in vortex at 4ºC. 
After centrifugation, supernatant was used for calcium quantification by the o-
cresolphtalein complexone method and the pellet was used to quantify the protein 
content.  
For the Alizarin red staining, cells incubated in calcification media were washed with 
PBS two times and then fixed with formaldehyde at RT for 15 min. After fixation cells 
were washed again and incubated with 40 mM alizarin red solution (Sigma A3757) at 
pH between 4,1-4,3 for 20 minutes. 
Determination of calcitriol production (1α-hydroxylase activity) 
After treatments or 1α-hydroxylase overexpression, cell monolayers were washed 6 
times with PBS and incubated with DMEM with or without 500 ng/mL of 25(OH)D3. 
After one hour, incubation media were collected and after sample delipidation with 
dextran sulphate and magnesium chloride, 100 ul of sample were run through a solid 
phase column coated with monoclonal antibodies against 1,25(OH)2D3. Afterwards, the 
column was eluted with ethanol and the collected fraction was evaporated under 
nitrogen atmosphere and resuspended in assay buffer. Levels of 1,25(OH)2D3 were then 
assessed by ELISA (Immunodiagnostics Systems). The production was calculated as 
follows: 1,25(OH)2D3 levels in the wells with 25(OH)D3 minus 1,25(OH)2D3 levels in 
wells without 25 (OH)D3. Serum samples were processes in the same way. The 
percentage of recovery, as reported by the manufacturer, was 96%. 
Real Time PCR 
Total cellular RNA from VSMC and from rat aortic tissue samples was extracted with 
TRIzol reagent (Sigma Aldrich), following manufacturer’s instructions. The final RNA 
concentration was determined by nanodrop (ND-100) spectrophotometer. Reverse 
transcription and real time PCR were performed as previously described.(36) Briefly, real 
time PCR with gene-specific TaqMan probes for rat and mouse VDR, 1α-hydroxylase, 
24-hydroxylase, RUNX2 and GAPDH as an endogenous control (Applied Biosystems) 
was performed with an ABI Prism 7000 Sequence Detection System (Applied 
Biosystems) using TaqMan Universal PCR Master Mix. Forty cycles at 95ºC for 15 
second and 60ºC for 1 minute were performed. Every experiment was carried out three 
times and all samples were amplified in triplicate  
The relative RNA amount was calculated by standard formulae and expressed as fold 
induction over controls. Average and standard error from three experiments performed 
in triplicate were calculated. 
Western Blot analysis 
Total cell lysates were obtained by washing the cell monolayer with cold PBS, 
scraping and suspending in lysis buffer (125 mM Tris, pH 6.8, 2% SDS, 2 mM PMSF 
and protease inhibitor cocktail). Samples were sonicated and the supernatant was 
collected after centrifugation for 10 minutes at 10000 rpm, 4ºC. Aortic tissue was 
homogenized in lysis buffer (50 mM Tris-HCl, pH 7,5, 1% Triton X-100, 150 mM 
NaCl, 1 mM DTT, 1 µM PMSF, 1 mM of Na3VO4 and protease inhibitor cocktail) using 
the TissueLyser LT (Qiagen): 4 cycles of homogenization (50 Hz for 2 min each cycle) 
followed by 3 cycles in liquid nitrogen and thawing at 37ºC. The supernatant was 
collected after centrifugation for 10 min at 10000 rpm, 4ºC. Protein concentration was 
determined using a DC protein assay kit (Bio-Rad).  25 µg of proteins were 
electrophoresed on 10% SDS-PAGE gels, and transferred to PVDF membranes 
(Immobilon-P, Millipore). Membranes were probed with primary antibodies against 
VDR (1:1000; Santa Cruz), CYP24 (1:1000; Santa Cruz), CYP27B1 (1:1000; Santa 
Cruz), RUNX2 (1:1000; Novus Biologicals), anti-V5 epitop (1:1000, Sigma), GAPDH 
(1:5000, Sigma), α-tubulin (1:5000; Sigma) and α-actin (1:500, Santa Cruz) over night 
at 4ºC. Corresponding peroxidase-conjugated secondary antibody: rabbit IgG+HRP 
(1:10000; Cell Signaling), mouse IgG+HRP (1:10000; Jackson Immunoresearch) or 
goat IgG+HRP (1:10000; Santa Cruz) were incubated for 1 hour at RT. The 
immunoreaction was visualized using chemiluminescent kits EZ ECL (Biological 
Industries) or ECL Advanced (Amersham Biosciences). Images were digitally acquired 
by VersaDoc Imaging system Model 4000 (Bio-Rad). Positive immunoreactive bands 
were quantified by densitometry and compared with the expression of adequate loading 
control. 
Overexpression of CYP27B1 in rat VSMC 
The 1α-hydroxylase gene (CYP27B1) was subcloned via gateway technology into the 
lentiviral plasmid pDSL (ATCC).  Production of lentiviral particles was done as 
previously described.(35) Empty FSV vector (EV) was used as a control of transfection. 
VSMC from rat between passages 3 and 5 were used for the experiment. 
Statistical Analysis 
Differences between groups were assessed by Student´s T test or by one-way ANOVA 
followed by Scheffe’s test. A p<0.05 was considered statistically significant. All data 
examined are expressed as mean ± SEM. 
 
RESULTS 
Uremia deregulates the expression of VDR, 1α-hydroxylase, 24-hydroxylase and 
induces calcification in rat artery in vivo. 
To study the effect of uremia in vivo, rats were subjected to 5/6 nephron reduction and 
sacrificed at week 8. Uremic rats displayed an increase in creatinine, calcium and PTH 
serum levels (Figure 1A) compared with controls. They also demonstrated a decrease in 
phosphate levels, indicating they were in the early stages of CKD. The analysis of 
vascular calcification by calcium quantification showed higher levels of calcium content 
in the arteries of uremic rats compared with the control rats (Figure 1 B) and an increase 
in alizarin red staining (Figure 1C). Figure 1 (D, E, F) shows the expression of VDR, 
1α-hydroxylase and 24-hydroxylase in the rat artery. Uremia significantly increased 1α-
hydroxylase and 24-hydroxylase expression at mRNA (Figure 1D) and protein level 
(Figure 1E) in the rat artery. An increase of VDR and RUNX2 in the artery of uremic 
rats was only observed at the protein level (Figure 1 E, F; data not shown for Runx2 
qPCR).  
Uremic patients with vascular calcification show increased immunostaining for 1α-
hydroxylase in epigastric arteries. 
To confirm whether an increase in vascular calcification was associated with an increase 
in the expression of arterial 1α-hydroxylase in patients, epigastric arteries were obtained 
from uremic patients subjected to a kidney transplant and from kidney donors. Vascular 
calcification was confirmed by an increase in the calcium levels in the epigastric arteries 
of uremic patients (Figure 2A). In parallel, immunostaining for 1α-hydroxylase was 
higher in arteries obtained from CKD patients than in arteries obtained from non-CKD 
donors (Figure 2B and C). 
Uremic serum deregulates the expression of VDR, 1α-hydroxylase and 24-
hydroxylase and induces calcification in rat VSMC. 
To examine the effect of uremia in vitro, rat VSMCs were incubated for 6 days in high 
phosphate media supplemented with serum obtained from normal rats (control serum) 
or from rats subjected to 5/6 nephrectomy maintained on a normal diet for 4 months 
(uremic serum). Uremic serum significantly increased the expression of VDR and 1α-
hydroxylase mRNA (Figure 3A) in VSMCs, while 24-hydroxylase expression was not 
modified. Figure 3B shows the western blot images of the same samples. The 
quantification in Figure 3C showed that levels of RUNX2 increased (although the 
increase was not significant) whereas levels of 1α-hydroxylase, 24-hydroxylase, and 
VDR increased significantly. The incubation of VSMCs with high P and uremic serum 
induced a dose-dependent increase in calcification as shown in Figure 3E. Alizarin red 
staining was also increased (Figure 3D). Furthermore, production of calcitriol was 
increased in cells treated with uremic serum compared with cells treated with control 
serum (Figure 3F). 
1α-hydroxylase has a direct effect on calcification in rat VSMC 
To study the role of 1α-hydroxylase in vascular calcification, we stably 
overexpressed 1α-hydroxylase in rat VSMCs (pDSL 1α-hydroxylase). An empty vector 
(EV) served as a control. Figure 4 shows an evident increase of 1α-hydroxylase protein 
fused with the epitope V5 (Figure 4A), as well as of 1α-hydroxylase mRNA (Figure 4B) 
in rat VSMCs. VSMCs overexpressing 1α-hydroxylase showed significantly elevated 
production of 1,25(OH)2D3 (Figure 4C), alongside markedly higher intracellular 
calcium content (Figure 4D) and alizarin red staining (Figure 4E) compared with the 
control cells (EV). Furthermore, VSMCs overexpressing 1α-hydroxylase showed an 
evident upregulation of RUNX2 protein expression compared with control group 
(Figure 4F). 
STN CYP27B1+/+ and CYP27B1-/- mice treated with calcitriol have similar serum 
levels of Ca, P, PTH and 1,25vitD. 
To further evaluate the role of locally produced calcitriol in vivo, we used a 
CYP27B1-/- mouse model with CKD. CYP27B1+/+ and CYP27B1-/- mice were subjected 
to subtotal nephrectomy and treated with calcitriol (400 ng/Kg) to equilibrate serum Ca, 
P, PTH, 1,25(OH)2D3 and to induce vascular calcification. Results showed similar levels 
of BUN in CYP27B1+/+ and CYP27B1-/- mice (Figure 5A), suggesting a similar degree 
of renal impairment. Calcium levels (Figure 5B), generally lower in CYP27B1-/- mice, 
increased with calcitriol treatment reaching similar levels as CYP27B1+/+ treated mice. 
Phosphate levels, which were comparable in both untreated mice groups, also increased 
to a similar degree when animals were treated with calcitriol (Figure 5C). Levels of 
PTH, which are very high in CYP27B1-/-  mice, decreased in both groups of animals 
treated with calcitriol reaching similar values (Figure 5D). 1,25(OH)2D3 levels, 
generally undetectable in CYP27B1-/- mice, raised to similar levels in both treated 
groups (Figure 5E). 
 
STN CYP27B1+/+ mice treated with calcitriol present more severe vascular 
calcification than STN CYP27B1-/-   treated mice. 
CYP27B1+/+ mice subjected to subtotal nephrectomy and treated with calcitriol 
showed significant increase of arterial calcium content compared with STN CYP27B1-/- 
mice underwent the same treatment (Figure 6A). Alizarin red staining (Figure 6B) 
showed an increase in calcium deposits in the artery of STN CYP27B1+/+ treated mice, 
which was not observed in CYP27B1-/-   animals. Furthermore, immunoreactivity for 
RUNX2, an essential regulator of VSMC´s calcification, was higher in the arteries of 
STN CYP27B1+/+ treated mice (Figure 6C) compared with STN CYP27B1-/- treated 
animals. 
 
 
 
Uremic serum does not affect the expression of RUNX2, VDR, 1α-hydroxylase and 
24-hydroxylase and does not induce vascular calcification in CYP27B1-/- VSMC. 
Representative western blots of RUNX2, VDR, 1α-hydroxylase, 24-hydroxylase 
in VSMC from CYP27B1+/+ and CYP27B1-/- treated with high phosphate media and 
control or uremic serum are shown in Figure 7A. Figure 7B shows quantification of the 
western blots. CYP27B1+/+ VSMC treated with uremic serum showed an increased 
expression of RUNX2 (although the quantification did not reach statistical significance 
Figure 7B), but was not modified in the VSMCs from CYP27B1-/- mice. VDR, 1α-
hydroxylase and 24-hydroxylase showed a significant increase in CYP27B1+/+ VSMC, 
while in CYP27B1-/- VSMC the treatment with uremic serum did not affect the 
expression of these proteins. Figure 7C shows data of mRNA levels obtained from real-
time PCR. Expression of RUNX2, 1α-hydroxylase and 24-hydroxylase significantly 
increased, while the expression of VDR, in contrast to the protein levels, decreased in 
CYP27B1+/+ VSMCs incubated with uremic serum (Figure 7C). However, in VSMCs 
from CYP27B1-/- mice, only the expression of 24-hydroxylase was slightly but 
significantly upregulated. Calcium levels were significantly elevated in CYP27B1+/+ 
VSMC treated with uremic serum whereas calcification did not increase in VSMCs 
from CYP27B1-/- mice (Figures 7D and E). 
 
DISCUSSION 
In this study, we show that an increase of the local expression of 1α-hydroxylase in 
VSMC is a mediator of the increase in vascular calcification observed in CKD. Thus, 
both in vitro and in vivo (in experimental animals and in patients), uremia-induced 
vascular calcification paralleled an increase in 1α-hydroxylase expression. Furthermore, 
in the absence of 1α-hydroxylase, the increase of calcification induced by uremia was 
blunted and the overexpression of 1α-hydroxylase was enough to induce vascular 
calcification in VSMC. 
1α-hydroxylase is expressed in the kidney and also in other tissues and cell types 
including VSMC, intestine (epithelial intestinal cells), lymphatic ganglia, prostate, 
spleen, monocytic cells, macrophages, dendritic cells, parathyroid cells, β-pancreatic 
cells and osteoblasts.(37) In those other cell types, regulation of its expression seems to 
be independent of the conventional regulators that affect its expression in tubular cells. 
Thus, Adams et al. have shown that macrophage 1α-hydroxylase expression in 
sarcoidosis is driven by proinflammatory cytokines.(38) In that condition the increased 
activity of 1α-hydroxylase would increase 1,25(OH)2D3 levels to supranormal 
concentrations.(39) Furthermore endothelial cells also show an upregulation of 1α-
hydroxylase levels by proinflammatory cytokines.(20) In placental tissue, the production 
of 1,25(OH)2D3 is upregulated by IGF-I(40) and in many cancer types, the expression of 
1α-hydroxylase is either upregulated or downregulated depending, in part, on the stage 
of progression of the cancer.(41) Therefore it seems clear that regulation of extrarenal 1α-
hydroxylase expression is tissue dependent and is modified in many different 
conditions. 
Chronic kidney disease is a condition in which systemic production of 1,25(OH)2D3 is 
altered. Thus, there is a decrease in circulating levels of 1,25(OH)2D3 due to a reduction 
of renal 1α-hydroxylase activity, an increase of 1,25(OH)2D3 degradation, and impaired 
uptake in tubular cells of 25(OH)D3, the substrate of 1α-hydroxylase.(42) However, 
macrophages from uremic patients show an increased, rather than decreased, 1α-
hydroxylase activity.(31) Our results show that vascular smooth muscle cells show 
similar regulation. Thus both, in vitro and in vivo, the uremic milieu increases the levels 
of 1α-hydroxylase in VSMC. The uremic factors that are involved in this upregulation 
of 1α-hydroxylase are unknown, but increased PTH levels or in inflammatory cytokines 
could be playing a role.  
Whether this increase of 1α-hydroxylase levels translate into an increase of intracellular 
1,25(OH)2D3 in vivo is unknown, and current techniques to determine those levels lack 
sufficient sensitivity. However, our in vitro data show that VSMC incubated in uremic 
media produce higher amounts of 1,25(OH)2D3 than cells incubated in normal media. In 
vivo data indirectly show an increase in VDR activation because both VDR and 24-
hydroxylase protein levels are upregulated suggesting that the increase in 1α-
hydroxylase levels activates VDR locally. The increase in VDR activation should 
directly downregulate 1α-hydroxylase expression. However, in macrophages the 
synthesis of 1,25(OH)2D3 is not self-inhibited, and this appears to be the basis for the 
unregulated 1α-hydroxylase activity,(43) showing that extra renal regulation of 1α-
hydroxylase could be less sensitive to autoregulation by 1,25(OH)2D3.(19) Therefore, the 
results point to an overactivation of VDR signaling in uremia, which has been 
previously shown to induce vascular calcification. Indeed, both in vivo and in vitro, 
supraphysiological levels of 1,25(OH)2D3 induce expression of osteoblastic genes like 
RUNX2 and vascular calcification. In our experiments, uremic conditions induced 
increases in RUNX2 expression and vascular calcification in vivo and in vitro. 
Our results also demonstrate that the increase in 1α-hydroxylase is necessary and 
sufficient to induce vascular calcification. Thus, overexpression of 1α-hydroxylase in 
VSMC increased both RUNX2 expression and vascular calcification. Furthermore, the 
elimination of 1α-hydroxylase totally inhibited the vascular calcification in vitro. 
Indeed, VSMC obtained from 1α-hydroxylase KO animals and incubated in 
calcification media showed no increase in RUNX2, calcium content nor in alizarin red 
staining, demonstrating that the presence of 1α-hydroxylase is necessary for the uremia-
induced vascular calcification. The in vitro data also show some puzzling results. Thus, 
CYP27B1-/- mice show basal protein levels of RunX2 lower than CYP27B1+/+ but 
similar mRNA expression levels. This could be explained by a regulation of RunX2 
levels by activated VDR at post-transcriptional or even post-translational level. This 
fact has been already demonstrated in the regulation of several proteins.(44,45) Thus, 
absence of activated VDR in CYP27B1-/- could affect RunX2 protein levels without 
altering gene expression. Furthermore, another discrepancy is observed in the effect of 
uremic in VDR levels in CYP27B1+/+ cells. In this case, uremic serum increases VDR 
protein levels but decreases mRNA at steady state. Uremic serum has been shown in our 
study to increase 1,25(OH)2D3 in our cells, increasing therefore the activation of VDR 
and, thus, inhibiting its degradation and explaining the higher levels of protein.(46) The 
decrease in mRNA levels could be explained by the existence of uremic toxins in serum 
that have been shown to inhibit the binding of activated VDR to certain Vitamin D 
responsive elements in the DNA, and therefore, decreasing the levels of transcription of 
some VDR activated genes.(47) In vivo results agree with the in vitro data. In our model 
of vascular calcification induced by subtotal nephrectomy, CYP27B1-/- animals treated 
with toxic doses of calcitriol showed significantly lower levels of vascular calcification 
and RUNX2 expression, compared to CYP27B1+/+ littermates, although calcium and 
phosphate levels were similar. The inhibition of calcification was not complete, as 
CYP27B1-/- animals still showed an increase of vascular calcification after treatment 
with calcitriol and a tendency (although not statistically significant) was seen after 5/6 
nephrectomy in the same animals. This can be explained by the multifactorial 
pathophysiology of vascular calcification. Thus, one significant pathophysiological 
component seems to be related to the increases in 1α-hydroxylase activity and another 
part is probably related to the increases in blood Ca and P, which are also very high in 
the CYP27B1-/- animals treated with calcitriol. Furthermore, the dose of calcitriol used 
was able to increase the blood concentrations of 1,25(OH)2D3 to similar levels in both 
groups, so differences in circulating levels of the hormone can be ruled out as the cause 
of this effect. 
In conclusion, our results point to a paramount role of local expression of 1α-
hydroxylase in VSMC in regulating uremia-induced vascular calcification. These results 
could be of importance to identify new treatments to reduce vascular calcification in 
CKD patients. 
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Figure Legends 
Figure 1. Uremia deregulates the expression of VDR, 1α-hydroxylase, 24 
hydroxylase and induces calcification in rat artery in vivo. (A) Levels of creatinine, 
calcium, phosphate and PTH in serum from control and uremic rats. (B) Aortic calcium 
content in control and uremic rats. (C) Alizarin red staining in arteries from control and 
uremic rats. (D) Expression of VDR, 1α-hydroxylase and 24-hydroxylase determined by 
qPCR in artery from control rats (black bars), and uremic rats (grey bars). (E) Protein 
expression of VDR, RUNX2, 24-hydroxylase and 1α-hydroxylase determined by 
Western blot in the artery from control and uremic rats. GAPDH was used as a loading 
control. (F) Quantitative analysis of western blots. Data are mean ± sem (n = 6) *: p < 
0.05 vs control (control rat). Scale bar represents 100  m. 
Figure 2. CKD patients with vascular calcification show an increase in arterial 
expression of 1α-hydroxylase. (A) Vascular calcium content form epigastric arteries 
obtained from CKD patients undergoing a renal transplant and from non-CKD kidney 
donors. (B) Immunohistochemistry for 1α-hydroxylase in the same arteries. (C) 
Quantification of the 1α-hydroxylase staining by histoscore.*:p<0.01 
Figure 3. Uremia deregulates the expression of VDR, 1α-hydroxylase, 24-
hydroxylase and induces calcification in vitro. VSMC treated with high phosphate 
media with 15% serum from healthy rat (control serum, black bars) or from 5/6 
nephrectomized rat (uremic serum, grey bars). (A) Expression of VDR, 1α-hydroxylase 
and 24-hydroxylase determined by qPCR after 48h of treatment. (B) Representative 
western blot assessing protein expression of RUNX2, VDR, 1α-hydroxylase and 24-
hydroxylase after 6 days of treatment. α-tubulin was used as a loading control. (C) 
Quantification of western blot. (D) Alizarin red staining (bright field pictures) in rat 
cells incubated with normal or uremic serum (15%). (E) Quantification of calcium 
content (micrograms of calcium per milligram of protein) in VSMC treated with high 
phosphate media and crescent concentrations of normal or uremic serum. (F) Production 
of 1,25(OH)2D3 in cells incubated with control or uremic serum. Data are mean ± sem (n 
= 6). *: p < 0.05 vs control serum. #: p<0.05 vs 10%. +: p<0.05 vs 15%. Scale bar 
represents 200  m.  
Figure 4. 1α-hydroxylase overexpression in rat VSMC increases calcification. (A) 
WB anti-V5-1α-hydroxylase to detect the overexpression in VSMC compared with the 
empty vector (EV). (B) Expression of 1α-hydroxylase in VSMC infected with the EV 
and PDSL-1α-hydroxylase determined by qPCR. (C) Production of 1,25(OH)2D3 in 
cells infected with the 1α-hydroxylase overexpression plasmid compared with cells 
infected with the empty vector. (D) Calcium content normalized to protein and (E) 
alizarin red staining in cells infected with the 1α-hydroxylase overexpression plasmid 
compared with cells infected with the empty vector. RUNX2 detection by western blot 
(F) in cells infected with the 1α-hydroxylase overexpression plasmid compared with 
cells infected with the empty vector. Data are reported as means ± sem (n = 12)*: p < 
0.05 vs VSMC without 1α-hydroxylase overexpression (EV). 
Figure 5. Subtotally nephrectomized (STN) CYP27B1+/+ and CYP27B1-/- mice 
treated with calcitriol have similar serum levels of Ca, P, PTH and 1,25(OH)2D3. 
Serum levels of (A) Blood urea nitrogen (BUN), (B) Calcium, (C) Phosphate, (D) PTH, 
(E) and 1,25(OH)2D3 in STN CYP27B1+/+ and STN CYP27B1-/- mice (black bars) and 
STN mice treated with calcitriol (grey bars). Data are reported as means ± sem (n = 8). 
*: p < 0.05 between STN and STN-treated mice, # p < 0.05 between CYP27B1+/+ and 
CYP27B1-/- mice.  
Figure 6. Subtotally nephrectomized (STN) CYP27B1+/+ mice treated with 
calcitriol show higher vascular calcification levels than STN-treated CYP27B1-/- 
mice. (A) Calcium content in abdominal aorta normalized by protein in STN 
CYP27B1+/+ and STN CYP27B1-/- mice treated with calcitriol (400ng/kg) for two 
weeks, and in control animals. (B) Representative histochemical of alizarin red staining 
and (C) immunohistochemical staining of RUNX2. Results are showed as mean ± sem 
(n=8) *: P<0.05 between STN and STN-treated mice. # P<0.05 between CYP27B1+/+ 
and CYP27B1-/- mice. Scale bar represents 100  m. 
Figure 7. Uremia does not affect calcification or the expression of RUNX2, VDR, 
1α-hydroxylase and 24-hydroxylase in CYP27B1-/- VSMCs.  (A) Representative 
Western blots assessing protein content for RUNX2, VDR, 1α-hydroxylase and 24-
hydroxylase in CYP27B1+/+ and CYP27B1-/- VSMCs treated with control or uremic 
serum. (B) Quantitative analysis of western blots. Data are expressed as fold change 
over wild type control levels. (C) Expression of RUNX2, VDR, 1α-hydroxylase and 24-
hydroxylase in CYP27B1+/+ and CYP27B1-/- VSMCs treated with control or uremic 
serum for 48 hours, determined by qPCR. Data are expressed as % over wild type 
control. (D) Quantification of calcium content normalized by mg of protein in VSMCs 
from CYP27B1+/+ or CYP27B1-/- mice treated with control or uremic serum for 6 days. 
(E) Alizarin red staining in VSMCs from CYP27B1+/+ or CYP27B1-/- mice treated with 
uremic serum for 6 days (bright field). Data are reported as means ± sem (n = 6) *: p < 
0.05 between control and uremic serum. #: p < 0.05 between WT and CYP27B1-/- 
VSMCs. 
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